by: Parent Project Muscular DystrophyWave Life Sciences joined PPMD for a community webinar on February 21, 2024 for an update on the company’s FORWARD-53 study. Wave provided an overview of initial clinical trial results for WVE-N531 in individuals with Duchenne muscular dystrophy who are amenable to exon 53 skipping, as well as an overview of the potentially registrational FORWARD-53 study.
